Table 1 Cell viability IC50 values for nine KIT-inhibitor TKIs in GIST cell lines

From: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

GIST CELL LINE

KIT MUTATION

IMATINIB

SUNITINIB

REGORAFENIB

SORAFENIB

NILOTINIB

PONATINIB

MASITINIB

DASATINIB

DOVITINIB

GIST-T1

Ex 11

4.5

5

35

30

15

4

15

4

4

GIST430

Ex 11

35

10

150

40

50

5

30

10

50

GIST882

Ex 13

300

70

800

300

350

50

350

150

500

GIST430/654

Ex 11 + Ex 13 (V654A)

2500

45

2000

800

850

100

3500

1000

250

GIST-T1/670

Ex 11 + Ex 14 (T670I)

>10,000

30

60

150

5000

5

10000

n.r.

200

GIST-T1/816

Ex 11 + Ex 17 (D816E)

1500

>10,000

550

650

500

40

6500

300

6000

GIST-T1/820

Ex 11 + Ex 17 (D820A)

1500

>10,000

600

600

400

25

3000

90

1200

GIST-T1/829

Ex 11 + Ex 18 (A829P)

3000

10000

2500

1500

650

25

>10,000

70

1500

GIST48B

KIT-independent

>10,000

>10,000

>10,000

>10,000

>10,000

1500

>10,000

>10,000

750

GIST226

KIT-independent

>10,000

>10,000

>10,000

>10,000

8000

6000

>10,000

>10,000

>10,000